Journal
GROWTH FACTORS
Volume 37, Issue 1-2, Pages 1-11Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/08977194.2019.1620227
Keywords
Interleukin; STAT3; signaling
Categories
Funding
- Victorian State Government Operational Infrastructure support Support Program
- National Health and Medical Research Council (NHMRC) of Australia [1080498, 1098643, 1147621]
- National Health and Medical Research Foundation
- National Health and Medical Research Council of Australia [1147621, 1098643, 1080498] Funding Source: NHMRC
Ask authors/readers for more resources
Interleukin (IL)-11 belongs to the IL-6 family of cytokines, discovered over 30 years ago. While early studies focused on the ability of IL-11 to stimulate megakaryocytopoiesis, the importance of this cytokine to inflammatory disease and cancers is only just beginning to be uncovered. This review outlines recent advances in our understanding of IL-11 biology, and highlights the development of novel therapeutics with the potential for clinical targeting of signaling by this cytokine in multiple diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
